Lilly Alzheimer's Drug Trial Yields Promising Sign

Published August 26, 2012

Lilly Alzheimer's drug trial yields promising sign

Filed under: drug treatment news 2012

By TOM MURPHY. AP Business Writer. By TOM MURPHY. Updated: 2012-08-24T21:18:29Z. More News. INDIANAPOLIS — An Alzheimer's treatment from Eli Lilly and Co. failed to slow memory decline in two separate patient studies, but the drug did show some …
Read more on Kansas City Star

Alnylam receives orphan drug designation from FDA for FAP treatment

Filed under: drug treatment news 2012

Aug 24, 2012 (Datamonitor via COMTEX) — Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, has received Orphan Drug Designation from FDA to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy, or FAP, one …
Read more on Equities.com